Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
SULTRIN is a triple sulfonamide vaginal cream combining sulfabenzamide, sulfacetamide, and sulfathiazole approved in 1945 for vaginal infections. It is a topical antimicrobial agent that works synergistically to inhibit bacterial growth in the vaginal mucosa. The product treats bacterial vaginosis and related gynecological infections.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), commercial teams should expect resource optimization and focus on generic transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on SULTRIN offers stability in a mature product portfolio but limited growth potential given its approaching loss of exclusivity. Career advancement on this product is best viewed as a stepping stone, with opportunities focused on managing the transition to generic competition and optimizing end-of-life commercial strategy.
Worked on SULTRIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.